A few weeks ago (March 14th), I described the outlandish process that led to the approval of the "dissociative anaesthetic" agent, esketamine as a nasal spray, for "treatment-resistant depression." Since then, we've had the ADHD bandwagon, pushed by no less than a senator, arrive in town for what threatens to be a long stay and, this week, the Royal Aus…
Keep reading with a 7-day free trial
Subscribe to Niall McLaren on Critical Psychiatry to keep reading this post and get 7 days of free access to the full post archives.